All articles by Phillip Broadwith
-
BusinessSanofi to buy Blueprint Medicines for over $9 billion
Blueprint has one approved drug and enhances Sanofi’s immunology portfolio
-
OpinionSafety is everyone’s responsibility
Maintaining culture and investment is key, especially in the absence of incidents
-
BusinessExplosion and fire at Chinese chemical plant kills five
Six others missing and 19 injured at Shandong Youdao Chemical
-
OpinionIgnoring women’s health shouldn’t be an option
Developing therapies for conditions that predominantly affect women is a neglected, but enormous, opportunity
-
OpinionRebuilding pharma supply chains
Multinationals are promising huge US investments, but it’s not all because of Trump’s policies
-
OpinionIran port explosion highlights issues of shipping hazardous chemicals
Intersecting regulations and jurisdictions mean rules can be accidentally or deliberately overlooked
-
BusinessAt least 70 dead in Iran port explosion and fire
More than 1000 people injured after cargo caught fire and exploded
-
BusinessMerck KGaA to buy cancer specialist SpringWorks
$3.9 billion deal boosts Merck’s pipeline as it faces patent expiries
-
BusinessGilead settles US HIV drug kickback lawsuit
Firm will pay $202 million to federal and state governments
-
OpinionGiving companies room to grow
Can shopping centres and offices become urban lab spaces for innovative companies to grow and scale-up?
-
BusinessAcceptable levels of (epi)genetic engineering
Amplifying or silencing genes may be preferable to permanently changing genetic code
-
OpinionTrump’s tariff stand-off
Piling cost and complexity to stretched global supply chains will hit industries hard
-
-
OpinionGetting into the weeds of the glyphosate debate
Assessments of the risk posed by the controversial herbicide depend on how the evidence is weighed
-
OpinionWeight loss drug supply races
With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of drugs
-
OpinionWhy companies are rushing to flatter Trump
Pharma firms are among many pausing diversity programmes and promising domestic investment
-
OpinionLearning to listen
Many things have changed in the last two decades, but effective collaboration is more important than ever
-
Feature20 years. 20 chemists. 20 stories. Part 2
How has chemistry changed in the last two decades?
-
ArticleDeadly explosion at US food colouring plant
2 workers dead, 11 injured at Givaudan Sense Colour in Louisville
-
